NZCA.F Provexis plc

Healthcare Pharmaceuticals Frankfurt Exchange
0.0065 EUR
Close of Nov 5, 2026
0.0005 0.0200
Market cap
EUR 15.2M
P/E
-
P/B
11.54x
ROE
-45.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is NZCA.F undervalued?

Graham number

The Graham number of Provexis plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Provexis plc fundamental analysis

No fundamental analysis for Provexis plc yet.

Provexis plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Provexis plc

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary suppl…

Full company profile